2025
Global estimates of rotavirus vaccine efficacy and effectiveness: a rapid review and meta-regression analysis
Prunas O, Asare E, Sajewski E, Li Y, Pithawala Z, Weinberger D, Warren J, Armah G, Cunliffe N, Iturriza-Gómara M, Lopman B, Pitzer V. Global estimates of rotavirus vaccine efficacy and effectiveness: a rapid review and meta-regression analysis. EClinicalMedicine 2025, 81: 103122. PMID: 40115174, PMCID: PMC11925534, DOI: 10.1016/j.eclinm.2025.103122.Peer-Reviewed Original ResearchRotavirus-associated gastroenteritisRotavirus vaccine efficacyPredicting vaccine efficacyVaccine efficacyVaccine effectivenessVaccine performanceNational rotavirus immunization programImpact of rotavirus vaccinationRotavirus immunization programAffecting young childrenBill &Meta-regression analysisRandomized controlled trialsSystematic review of studiesEstimates of vaccine effectivenessRotavirus morbidityMelinda Gates FoundationRotavirus vaccineCohort studyLicensed vaccinesVaccine trialsDecreased efficacyControlled trialsCase-controlLow-income settingsEstimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization
Wong A, Warren J, Fitch L, Perniciaro S, Dagan R, Weinberger D. Estimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization. The Journal Of Infectious Diseases 2025, jiaf106. PMID: 40036886, DOI: 10.1093/infdis/jiaf106.Peer-Reviewed Original ResearchHigher-valent PCVsPneumococcal conjugate vaccinePneumococcal colonizationVaccine-induced serum antibodiesRisk of colonizationSerum immunoglobulin GRandomized controlled trialsConjugate vaccinePCV13Clinical trialsSerum IgGImmune responseVaccinated childrenSevere diseaseVaccine effectivenessSerum antibodiesPCV20Serotype-specificImmunoglobulin GSerotypesColonIndirect protectionIgGVaccineTrials
2024
Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV
Prunas O, Willemsen J, Warren J, Bont L, Schwartz J, Atwell J, Begier E, Dean N, Hirsch I, Karron R, Klugman K, Kramer R, Leidman E, Link-Gelles R, Nair H, Panozzo C, Pelfrene E, Simões E, Smith P, Srikantiah P, Sundaram M, Thindwa D, Vaughn D, Wilson E, Zar H, Pitzer V, Weinberger D. Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV. Vaccine X 2024, 19: 100509. DOI: 10.1016/j.jvacx.2024.100509.Peer-Reviewed Original ResearchRespiratory syncytial virusRandomized controlled trialsPreventive therapyPrevention of respiratory syncytial virusTrial designSuccess of randomized controlled trialsVaccine trial designDesign randomized controlled trialClinical trial designEstimates of vaccine efficacyPrimary endpointSyncytial virusClinical trialsVaccine efficacyControlled trialsMeta-regression modelsSelection of primary endpointsEndpointSequential trial designTherapyMultiple endpoints
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply